List of Cadent Therapeutics patents

List of Cadent Therapeutics patents

List of La Marzocco patents

List of Biscom patents

List of Sealed Air patents

List of awards received by Brad Faxon

Companies in the Securities, Commodity Contracts, and Other Financial Investments and Related Activities industry

Patents where

Current Assignee

Name

is

Cadent Therapeutics

	Name	Description	Patent Applicant	Current Assignee	Inventor	Patent Jurisdiction	Patent Number	Date of Patent
	‌ US Patent 10584131 Heteroaromatic NMDA receptor modulators and uses thereof	Patent 10584131 was granted and assigned to Cadent Therapeutics on March, 2020 by the United States Patent and Trademark Office.	Cadent Therapeutics	Cadent Therapeutics		United States Patent and Trademark Office	10584131	March 10, 2020
	‌ US Patent 11541057 Thienopyrimidinone NMDA receptor modulators and uses thereof		Cadent Therapeutics	Cadent Therapeutics		United States Patent and Trademark Office	11541057	January 3, 2023
	‌ US Patent 11542264 Heteroaromatic NMDA receptor modulators and uses thereof	Patent 11542264 was granted and assigned to Cadent Therapeutics on January, 2023 by the United States Patent and Trademark Office.	Cadent Therapeutics	Cadent Therapeutics		United States Patent and Trademark Office	11542264	January 3, 2023
	‌ US Patent 10500205 Thienopyrimidinone NMDA receptor modulators and uses thereof	Patent 10500205 was granted and assigned to Cadent Therapeutics on December, 2019 by the United States Patent and Trademark Office.	Cadent Therapeutics	Cadent Therapeutics		United States Patent and Trademark Office	10500205	December 10, 2019
	‌ US Patent 11274107 NMDA receptor modulators and uses thereof	Patent 11274107 was granted and assigned to Cadent Therapeutics on March, 2022 by the United States Patent and Trademark Office.	Cadent Therapeutics	Cadent Therapeutics		United States Patent and Trademark Office	11274107	March 15, 2022
	‌ US Patent 10351553 Potassium channel modulators	Patent 10351553 was granted and assigned to Cadent Therapeutics on July, 2019 by the United States Patent and Trademark Office.	Cadent Therapeutics	Cadent Therapeutics		United States Patent and Trademark Office	10351553	July 16, 2019
	‌ US Patent 9975886 Potassium channel modulators	Patent 9975886 was granted and assigned to Cadent Therapeutics on May, 2018 by the United States Patent and Trademark Office.	Cadent Therapeutics	Cadent Therapeutics		United States Patent and Trademark Office	9975886	May 22, 2018
	‌ US Patent 10973825 Thienopyrimidinone NMDA receptor modulators and uses thereof	Patent 10973825 was granted and assigned to Cadent Therapeutics on April, 2021 by the United States Patent and Trademark Office.	Cadent Therapeutics	Cadent Therapeutics		United States Patent and Trademark Office	10973825	April 13, 2021
	‌ US Patent 10752633 Heteroaromatic NMDA receptor modulators and uses thereof		Cadent Therapeutics	Cadent Therapeutics		United States Patent and Trademark Office	10752633	August 25, 2020
	‌ US Patent 10626122 Heteroaromatic NMDA receptor modulators and uses thereof		Cadent Therapeutics	Cadent Therapeutics		United States Patent and Trademark Office	10626122	April 21, 2020
	‌ US Patent 11236104 Heteroaromatic NMDA receptor modulators and uses thereof	Patent 11236104 was granted and assigned to Cadent Therapeutics on February, 2022 by the United States Patent and Trademark Office.	Cadent Therapeutics	Cadent Therapeutics		United States Patent and Trademark Office	11236104	February 1, 2022
	‌ US Patent 11116749 Selective octahydro-cyclopenta[c]pyrrole negative modulators of NR2B	Patent 11116749 was granted and assigned to Cadent Therapeutics on September, 2021 by the United States Patent and Trademark Office.	Cadent Therapeutics	Cadent Therapeutics		United States Patent and Trademark Office	11116749	September 14, 2021
	‌ US Patent 10774064 Potassium channel modulators	Patent 10774064 was granted and assigned to Cadent Therapeutics on September, 2020 by the United States Patent and Trademark Office.	Cadent Therapeutics	Cadent Therapeutics		United States Patent and Trademark Office	10774064	September 15, 2020
	‌ US Patent 10717728 Potassium channel modulators	Patent 10717728 was granted and assigned to Cadent Therapeutics on July, 2020 by the United States Patent and Trademark Office.	Cadent Therapeutics	Cadent Therapeutics		United States Patent and Trademark Office	10717728	July 21, 2020
	‌ US Patent 10781174 N-alkylaryl-5-oxyaryl-octahydro-cyclopenta[C]pyrrole negative allosteric modulators of NR2B		Cadent Therapeutics	Cadent Therapeutics		United States Patent and Trademark Office	10781174	September 22, 2020
	‌ US Patent 10239835 N-alkylaryl-5-oxyaryl-octahydro-cyclopenta[c]pyrrole negative allosteric modulators of NR2B	Patent 10239835 was granted and assigned to Cadent Therapeutics on March, 2019 by the United States Patent and Trademark Office.		Cadent Therapeutics		United States Patent and Trademark Office	10239835	March 26, 2019
	‌ US Patent 10052306 Selective octahydro-cyclopenta[C] pyrrole negative modulators of NR2B	Patent 10052306 was granted and assigned to Cadent Therapeutics on August, 2018 by the United States Patent and Trademark Office.		Cadent Therapeutics		United States Patent and Trademark Office	10052306	August 21, 2018

17 results

0 selected

17 results

0 selected